- PLN212.92m
- PLN295.83m
- PLN42.01m
Brief: Biomed Lublin Says Maksymilian Świniarski To Start CEO Duties On Oct 1
Brief: Biomed Lublin Sets Issue Price Of S Series Shares At 10.59 Zlotys/Shr
Brief: Biomed Lublin Appoints Maksymilian Swiniarski As CEO From 2022
Brief: Biomed Lublin Raises 13.4 Mln Zlotys From Sale Of Shares Loaned From Selected Shareholders
Brief: Biomed-Lublin Gets 43.2 Mln Zloty Subsidy For Onko BCG Production Plant
Brief: Biomed Lublin H1 Net Profit Up At 1.8 Mln Zlotys
Brief: Biomed-Lublin Repays 6 Million Zloty Loan Ahead Of Schedule
Brief: Biomed-Lublin Q1 Net Result Turns To Loss Of 1.2 Mln Zlotys
Brief: Biomed Lublin Resolves To Modify Process Of Financing Acquisition
Poland - Factors to Watch April 9
Brief: Biomed Lublin Signs Investment Deal And Offering Deal With Ipopema Securities
Brief: Biomed Lublin Starts Talks With ABM On Commercialising Use Of Immunoglobulin On COVID-19 Patients
Brief: Biomed Lublin FY Net Profit Up At 4.4 Mln Zlotys
Brief: Biomed Lublin Signs Term Sheet With Apogepha On Financial Deal For Onko BCG Development
Brief: Biomed Lublin Says Partner's Offer Chosen In Tender For Tuberculosis Vaccine
Brief: Biomed Lublin Says Medicines Authority Approves Running Clinical Trial For Anti SARS-CoV-2 Immunoglobulin
Brief: Biomed Lublin Says CEO Marcin Pirog Resigns
Brief: Biomed Lublin Says Hospital Files For Clinical Tests Regarding Immunoglobulina anty SARS-CoV-2
Brief: Biomed Lublin Q3 Net Profit Down At 94,000 Zlotys